Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 50,490 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 50,490 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer owned 27,046 shares in the company, valued at $1,051,278.02. The trade was a 65.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $38.90 on Thursday. The firm’s fifty day simple moving average is $36.20 and its 200-day simple moving average is $30.08. The company has a market capitalization of $2.88 billion, a P/E ratio of 972.74 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $39.79.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 568 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International during the second quarter worth $31,000. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International during the third quarter worth $32,000. Finally, US Bancorp DE purchased a new position in Kiniksa Pharmaceuticals International during the first quarter valued at $33,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a report on Monday, October 13th. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.